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Abstract
Extended-spectrum β-lactamase (ESBL) production and the prevalence of the β-lactamase-
encoding gene blaTEM were determined in Prevotella isolates (n = 50) cultured from the 
respiratory tract of adults and young people with cystic fibrosis (CF). Time–kill studies were used 
to investigate the concept of passive antibiotic resistance and to ascertain whether a β-lactamase-
positive Prevotella isolate can protect a recognised CF pathogen from the action of ceftazidime in 
vitro. The results indicated that approximately three-quarters (38/50; 76%) of Prevotella isolates 
produced ESBLs. Isolates positive for ESBL production had higher minimum inhibitory 
concentrations (MICs) of β-lactam antibiotics compared with isolates negative for production of 
ESBLs (P < 0.001). The blaTEM gene was detected more frequently in CF Prevotella isolates from 
paediatric patients compared with isolates from adults (P = 0.002), with sequence analysis 
demonstrating that 21/22 (95%) partial blaTEM genes detected were identical to blaTEM-116. 
Furthermore, a β-lactamase-positive Prevotella isolate protected Pseudomonas aeruginosa from 
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the antimicrobial effects of ceftazidime (P = 0.03). Prevotella isolated from the CF respiratory 
microbiota produce ESBLs and may influence the pathogenesis of chronic lung infection via 
indirect methods, including shielding recognised pathogens from the action of ceftazidime.
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1. Introduction
Prevotella spp. are dominant obligate anaerobic bacteria belonging to the oral and 
respiratory microbiota. They have been shown to occur in healthy individuals and in people 
with chronic pulmonary infection including cystic fibrosis (CF), chronic obstructive 
pulmonary disease and bronchiectasis [1–8]. This opportunistic pathogen has the potential to 
produce virulence factors that inhibit the action of antibiotics, facilitate immune evasion and 
contribute to tissue degradation [9,10]. Nevertheless, the pathogenesis of Prevotella 
infection in chronic polymicrobial lung diseases is not understood.
Pulmonary infection in CF is managed using a range of antimicrobial agents, including β-
lactam antibiotics, which target pathogens such as Pseudomonas aeruginosa [11]. Although 
Prevotella spp. are not currently targeted by antibiotic treatment of chronic lung infections, 
we recently detected resistance to penicillin and cephalosporin antibiotics in CF isolates 
from this genus, with reduced susceptibility associated with β-lactamase production [9]. 
Extended-spectrum β-lactamases (ESBLs), classed in functional subgroup 2be, including 
those encoded by a TEM-type β-lactamase gene (blaTEM), are known to confer resistance to 
such β-lactam antibiotics [12]. ESBL-producing bacteria have also been associated with 
clinical failure of cephalosporin antibiotics and increased mortality in hospital-acquired 
infections [13,14]. These data suggest that it may be clinically important to determine 
whether Prevotella spp. specifically produce ESBLs, which is currently unknown. 
Furthermore, in polymicrobial infections, β-lactamase-producing bacteria may protect β-
lactam-susceptible members of the community from antimicrobial agents [15]. Therefore, β-
lactamase production by Prevotella spp. may be an indirect method by which this genus 
contributes to disease pathogenesis in CF by enabling recognised pathogens to persist in the 
presence of β-lactam antibiotics.
The objective of this study was to investigate the production of ESBLs by clinical Prevotella 
isolates (n = 50) from the respiratory microbiota of adults and young people with CF and to 
establish the prevalence of blaTEM among these isolates. We also investigated the concept of 
passive resistance and hypothesised that a β-lactamase-producing Prevotella isolate could 
protect a P. aeruginosa isolate (from CF sputum) from the action of ceftazidime, an 
antibiotic commonly used in the treatment of CF pulmonary exacerbations.
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2. Materials and methods
2.1. Clinical Prevotella isolates
Fifty Prevotella isolates from people with CF living in Northern Ireland were included in 
this study to investigate ESBL production. The CF isolates were cultured from 14 adult (≥18 
years) CF patients attending the adult CF clinic, Belfast, UK (sputum, n = 25) and 11 
paediatric (6–17 years) CF patients attending the paediatric CF clinic, Belfast, UK (sputum, 
n = 4; cough swab, n = 21). The isolates originated from single bacterial colonies with 
different morphotypes from each clinical sample and those identified as Prevotella spp. were 
subsequently used in this study. Isolates were identified via 16S rRNA sequencing (Fig. A1, 
Appendix). Current prescription of long-term antibiotics (flucloxacillin, azithromycin, 
tobramycin and colistin) was documented for each CF patient (Table A1, Appendix).
2.2. Extended-spectrum β-lactamase production by Prevotella
Prevotella isolates (n = 50) were tested for production of ESBLs under strict anaerobic 
conditions using the combined disk method according to the manufacturer’s instructions. 
Briefly, each isolate was inoculated onto supplemented Brucella blood agar (SBBA) with 
disks (Neo-Sensitabs™; Rosco Diagnostica, Taastrup, Denmark) containing the indicator 
cephalosporins (ceftazidime 30 μg and cefotaxime 30 μg) as well as ceftazidime + clavulanic 
acid (30 μg + 10 μg) and cefotaxime + clavulanic acid (30 μg + 10 μg). Isolates were classed 
as ESBL-positive or ESBL-negative according to Clinical and Laboratory Standard Institute 
(CLSI) guidelines [16] as follows: isolates were identified as ESBL-positive if the diameter 
of the inhibition zone was increased by ≥5 mm when the tested indicator cephalosporin was 
combined with clavulanic acid for at least one of the combinations; and isolates were 
identified as ESBL-negative if the difference between the zone diameters was <5 mm for 
both combinations. Klebsiella pneumoniae ATCC 700603 was used as a quality control 
strain.
2.3. Susceptibility of Prevotella isolates to β-lactam antibiotics
Amoxicillin, ceftazidime and amoxicillin/clavulanic acid (AMC) were selected for in vitro 
susceptibility testing as these β-lactams are among the antibiotics recommended for the 
treatment of CF respiratory infection according to clinical guidelines [17]. Under strict 
anaerobic conditions, Prevotella isolates (n = 50) were inoculated onto SBBA and the 
minimum inhibitory concentrations (MICs) determined by Etest (bioMérieux, Marcy-
l’Étoile, France) according to the manufacturer’s instructions. Streptococcus pneumoniae 
ATCC 49619 (amoxicillin), P. aeruginosa ATCC 27853 (ceftazidime) and Bacteroides 
fragilis ATCC 25285 (AMC) were used as quality control strains. Where anaerobic 
breakpoints are available, isolates were categorised as susceptible, intermediate-resistant or 
resistant as defined by CLSI guidelines [18].
2.4. PCR amplification of blaTEM and DNA sequencing
DNA extraction was performed as previously described [19]. An alignment of 109 different 
blaTEM-type nucleotide sequences (861 bp, downloaded from BLAST) was used to identify 
consensus regions for primer annealing. Primers (blaTEM-Forward, 5′-CCG AAG AAC 
Sherrard et al. Page 3









GTT TTC CAA TG-3′; and blaTEM-Reverse, 5′-GAA GCT AGA GTA AGT AGT TCG-3′) 
had 100% coverage with the reference sequences and were purchased from Eurofins MWG 
Operon (Wolverhampton, UK). The PCR screening assay was performed using MyTaq™ 
Red Mix (Bioline, London, UK). The final reaction mixture (50 μL) contained 0.2 μM of 
each forward and reverse primer and 2 μL of DNA template. Escherichia coli NCTC 11560 
(blaTEM-1) was used as a positive control. PCR was performed using an Applied 
Biosystems® Veriti® Thermal Cycler (Thermo Fisher Scientific, Paisley, UK) with the 
following parameters: initial denaturation at 94 °C for 5 min; 33 cycles of denaturation at 94 
°C for 1 min, annealing at 55 °C for 1 min and extension at 72 °C for 1.5 min; and a final 
extension at 72 °C for 10 min. Amplicons (424 bp) were analysed as previously described 
[19]. PCR products positive for blaTEM were purified using a QIAquick® PCR Purification 
Kit (QIAGEN, Manchester, UK) in accordance with the manufacturer’s instructions. Both 
strands of DNA were sequenced by Eurofins MWG Operon using the forward and reverse 
primers, and a consensus DNA sequence was determined with CLUSTALW software. The 
deduced nucleotide sequences were compared with sequences deposited in GenBank.
2.5. Passive resistance
A β-lactamase-positive Prevotella isolate (ceftazidime MIC > 256 mg/L) and a β-lactamase-
negative P. aeruginosa isolate (ceftazidime MIC = 0.5 mg/L) (cultured from CF sputum and 
identified using 16S rRNA sequencing) were selected to investigate the concept of passive 
resistance [15].
Time–kill studies were carried out under strict anaerobic conditions according to CLSI 
guidelines [20]. Assays (Prevotella monoculture, P. aeruginosa monoculture and co-culture) 
were performed using basal anaerobic medium containing 1% w/v potassium nitrate (details 
of this medium are provided in the Appendix) and a cephalosporin antibiotic (ceftazidime; 
AAH Pharmaceuticals, Belfast, UK) at a predetermined concentration of 64× (32 mg/L) the 
P. aeruginosa MIC; this concentration has also been detected in CF sputum [21]. The initial 
inoculum of each bacterium was prepared to ca. 5 × 105 CFU/mL. No drug assays were 
included as controls. Killing activity was assessed at 0, 2, 4, 6, 24 and 48 h and was repeated 
on three different occasions with colonies enumerated on SBBA (under anaerobic 
conditions) and on Mueller–Hinton agar (under aerobic conditions) for the Prevotella and P. 
aeruginosa isolates, respectively. Drug carry-over was minimised by carrying out serial 
dilutions (10−1 to 10−6) in sterile saline.
A protective effect (antagonism) by Prevotella was defined as a ≥2 log10 increase in viable 
count of P. aeruginosa at 48 h compared with that of the P. aeruginosa isolate alone [22]. 
The limit of detection was 2 × 102 CFU/mL. To investigate whether survival of P. 
aeruginosa in the presence of Prevotella was secondary to the development of ceftazidime 
resistance, susceptibility testing (Etest) was performed using individual colonies (n = 10) 
isolated from the co-culture.
2.6. Statistical analysis
As the combined disk method is not routinely used to analyse ESBL production in 
Prevotella spp., a Spearman’s rank correlation coefficient was used to measure the degree of 
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association between zone diameter in the ESBL detection assay and susceptibility (MICs) to 
β-lactams. MICs were compared in ESBL-positive versus ESBL-negative isolates using the 
Mann–Whitney test. The prevalence of ESBL-producing isolates cultured from CF patients 
currently prescribed long-term antibiotics (flucloxacillin, azithromycin, tobramycin and 
colistin) compared with CF patients not prescribed these antibiotics was also determined 
using a χ2 test with Yates continuity correction or Fisher’s exact test. To investigate whether 
there was an association between the number of long-term antibiotics prescribed (0, 1, 2 or 
≥3) and detection of ESBL-producing Prevotella isolates, Fisher’s exact test was used. A χ2 
test with Yates continuity correction was also utilised to determine whether there was 
evidence of an association between ESBL production or detection of blaTEM and Prevotella 
group (CF adult versus CF paediatric patients). The total viable count (log10 CFU/mL) of P. 
aeruginosa in the presence of ceftazidime ± Prevotella was compared using a paired 
samples t-test. All statistical analyses were carried out with IBM SPSS Statistics for 
Windows v.21.0 (IBM Corp., Armonk, NY). A two-tailed P-value of <0.05 was considered 
statistically significant.
3. Results
3.1. Extended-spectrum β-lactamase production
ESBL production was common among Prevotella isolates from people with CF and was 
associated with high MICs of β-lactam antibiotics. Fig. A1 summaries ESBL production 
among the different clinical Prevotella spp. isolated from adult and paediatric CF patients 
(Appendix). The size of the measured zones of inhibition, obtained with the combined disk 
assay compared with MICs of the β-lactam antibiotics in ESBL-positive and ESBL-negative 
Prevotella isolates are summarised in the Appendix (Fig. A2). There was a strong inverse 
relationship in all analyses between zone diameter of the indicator cephalosporin antibiotics 
and susceptibility, with higher MICs of amoxicillin, ceftazidime and AMC associated with 
smaller zones of inhibition (P < 0.001) (Fig. A2, Appendix). Several ESBL-positive 
Prevotella isolates were identified as having apparently weak enzyme activity; these isolates 
had low MICs with correspondingly large zones of inhibition and clustered with the ESBL-
negative isolates (Fig. A2, Appendix). Similar weak in vitro ESBL activities have been 
identified in other bacterial genera and correlated with clinical failure in patients [13].
Approximately three-quarters of isolates tested (38/50; 76%) were classed as ESBL-positive. 
MIC results are summarised in Table 1. Resistance to the three β-lactam antibiotics was 
higher in ESBL-positive isolates compared with ESBL-negative isolates as demonstrated by 
higher MIC50 and MIC90 values among the former group. Furthermore, 23 (61%) of the 38 
ESBL-producing isolates were also categorised as resistant (n = 15) or intermediate-resistant 
(n = 8) to AMC. In contrast, all ESBL-negative isolates (n = 12) were susceptible to AMC. 
Moreover, the ESBL-positive isolates had significantly higher MICs of amoxicillin, 
ceftazidime and AMC compared with ESBL-negative isolates (P < 0.001, Mann–Whitney 
test) (Fig. 1). The Appendix also details ESBL production by multiple Prevotella isolates 
cultured from an individual clinical sample provided by some people with CF (n = 18) 
(Table A2); the majority of people either harboured ESBL-positive isolates only (10/18; 
56%) or both ESBL-positive and ESBL-negative isolates (7/18; 39%).
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3.2. Long-term prescription of antibiotics
Long-term antibiotic pressure may select for antibiotic resistance [11], and in our CF patient 
cohort four oral or inhaled antibiotics were prescribed chronically (oral: azithromycin and 
flucloxacillin; inhaled: tobramycin and colistin) (Table A1, Appendix). Therefore, we 
determined whether there was an association between detection of ESBL-producing isolates 
in patients currently prescribed these long-term antibiotic treatments compared with patients 
not prescribed the antibiotics. A similar percentage of ESBL-producing isolates was 
recovered from both groups (Fig. 2). In addition, we analysed whether there was a 
correlation between detection of ESBL-producing isolates and current chronic prescription 
of 0 (ESBL-positive, 86%), 1 (ESBL-positive, 83%), 2 (ESBL-positive, 67%) or ≥3 (ESBL-
positive, 63%) antibiotics (Table A1, Appendix). As the number of long-term antibiotic 
treatments prescribed increased, the prevalence of ESBL-producing Prevotella isolates 
decreased; however, no statistical difference was detected (P = 0.180, Fisher’s exact test).
3.3. The blaTEM gene
Twenty-two (44%) of the fifty clinical Prevotella isolates and E. coli NCTC 11560 were 
positive for blaTEM using the PCR screening assay. Sequence analysis revealed that of the 
22 blaTEM partial genes (ca. 400 bp) from Prevotella, 21 (95%) sequences had 100% 
identity with blaTEM-116. As expected, the partial nucleotide sequence from E. coli NCTC 
11560 had 100% identify with blaTEM-1. Furthermore, 18/22 (82%) blaTEM-positive 
Prevotella isolates were also positive for ESBL production using the combined disk method.
3.4. Prevotella isolates from paediatric or adult cystic fibrosis patients
ESBL production and presence of blaTEM were compared between those isolates cultured 
from adult versus paediatric CF patients. There was no association between CF group (adult 
versus paediatric) and ESBL production (P = 0.74, χ2 = 0.110) (Fig. 3), with 20/25 isolates 
(80%) from adult patients and 18/25 isolates (72%) from paediatric patients positive for 
ESBL production. However, a significant association was identified between CF group 
(adult versus paediatric) and the presence of blaTEM; 5 (20%) of 25 isolates from adult 
patients were positive for the gene compared with 17/25 (68%) isolates from paediatric 
patients (P = 0.002, χ2 = 9.821) (Fig. 3).
3.5. Passive resistance
As polymicrobial lung infection is frequent in CF, we tested whether Prevotella may shield 
P. aeruginosa from antibiotics. At 48 h (Fig. 4), the difference in P. aeruginosa viable count 
between the co-culture and monoculture was >2 log10 CFU/mL [mean co-culture viable 
count, 1.63 × 106 CFU/mL; mono-culture, <2 × 102 CFU/mL (limit of detection)], 
indicating a protective effect by the β-lactamase-positive Prevotella isolate. Moreover, the 
difference in total viable count of P. aeruginosa at this time point was statistically greater 
when cultured with compared to without the Prevotella isolate (P = 0.03, paired samples t-
test) (Fig. 4). We also found that survival of P. aeruginosa in the presence of Prevotella was 
not secondary to development of ceftazidime resistance [mean MIC = 0.22 mg/L (n = 10)].
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The Prevotella genus is commonly identified as belonging to the respiratory microbiota in 
people with chronic lung disease using molecular methods [1,2,8], and complex culture 
methods also detect Prevotella spp. in approximately one-third of CF pulmonary samples 
[4]. Despite evidence demonstrating the clinical importance of Prevotella at other body sites 
[23], we do not currently understand the role of this obligate anaerobe in infection and 
inflammation in chronic lung diseases. This is the first study to show that production of 
ESBLs is common among CF Prevotella isolates, which was associated with reduced 
susceptibility to β-lactam antibiotics. Future studies determining Prevotella susceptibility 
should consider production of this enzyme as a potentially important mechanism of 
resistance. We also present novel work investigating how β-lactamase-producing isolates 
from this genus may contribute to the pathogenesis of chronic lung infection and found that 
a β-lactamase-positive Prevotella isolate could shield P. aeruginosa from the antimicrobial 
action of ceftazidime.
Using the nitrocefin test [9], we previously identified that a high number of clinical 
Prevotella isolates from CF and non-CF sources produced β-lactamases (91/153; 59%). In 
this earlier study, we also found that β-lactamase production was correlated with reduced 
susceptibility to ceftazidime [9]. ESBLs, which belong to functional subgroup 2be [12], are 
one type of β-lactamase that have been associated with this spectrum of activity. ESBLs 
have also been associated with treatment failure with cephalosporin antibiotics and increased 
mortality in nosocomial infections [13,14]. However, in vitro production of ESBLs by 
Prevotella spp. has not been extensively investigated, with a single bacteraemia isolate 
identified as ESBL-positive in a case study reported by Mory et al. [24]. The combined disk 
method is used by clinical laboratories to confirm production of ESBLs [12]. In the current 
study, 38/50 (76%) Prevotella isolates tested were ESBL-positive using this method, and 
production of the enzyme was associated with significantly higher MICs of amoxicillin and 
ceftazidime. Although ESBLs are characteristically inhibited by clavulanic acid [12], the 
ESBL-positive isolates in this study also demonstrated reduced susceptibility to AMC. 
Mechanisms that may confer resistance to AMC include limiting access of the antibiotic to 
the target site via reduced permeability and expression of efflux pumps [19]. We previously 
demonstrated that expression of efflux pumps was not associated with AMC resistance 
amongst Prevotella spp. [19]; however, the role of outer membrane porins and reduced 
susceptibility to this antibiotic could be investigated.
Chronic antibiotic use has been correlated with an increased prevalence of multidrug-
resistant bacteria in CF [11]. Long-term antibiotic treatments were commonly prescribed in 
the CF patient cohort included in this study and this fact prompted us to investigate the 
effect of such chronic antibiotic use on the prevalence of ESBL-positive Prevotella isolates 
[11]. However, no difference was detected between patients currently prescribed or not 
prescribed chronic antibiotic treatments and detection of ESBL-positive isolates. 
Intermittent episodes of acute pulmonary exacerbations are treated with additional 
antibiotics in CF. The effect of such short-term antibiotic use on ESBL-production among 
Prevotella isolates could form the basis of future studies.
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Multiple blaTEM-type genes have been described, which belong to functional subgroups 2b, 
2be, 2br and 2ber β-lactamases; these subgroups reflect the enzymes substrate spectrum 
[12]. For example, blaTEM-1 and blaTEM-2 encode β-lactamases that belong to subgroup 2b 
and confer resistance to penicillins and some cephalosporin antibiotics [12]. Amino acid 
substitutions within these two β-lactamases subsequently led to the description of ESBLs, in 
subgroup 2be, with a broadened spectrum of activity that includes the oxyimino-β-lactams 
such as ceftazidime [12]. Previously, blaTEM was found in 1/4 (25%) Prevotella endodontic 
strains tested [25]. In the current study, we detected blaTEM in 22/50 (44%) isolates using 
PCR-based detection. Sequence analysis revealed that 21/22 (95%) partial blaTEM 
nucleotide sequences had 100% identity with blaTEM-116. This gene has been detected 
previously in E. coli and K. pneumoniae isolates and was associated with high MICs against 
a range of β-lactam antibiotics including ceftazidime [26]. We also showed that 18/38 (47%) 
ESBL-positive isolates harboured blaTEM. Although these data provide some evidence to 
suggest that blaTEM, associated with Prevotella isolates, encodes an ESBL, further work is 
required to confirm this hypothesis. To characterise the role of this gene in antibiotic 
resistance in Prevotella, β-lactam susceptibility could be determined in a blaTEM knock-out 
strain. Furthermore, the results of this study potentially suggest that blaTEM detected 
amongst CF Prevotella isolates is geographically clustered: all isolates were cultured from 
people living in Northern Ireland and we observed the majority of isolates to harbour the 
same partial blaTEM-type gene.
We cannot discount that other isolates included in this study did not harbour blaTEM owing 
to our primers not recognising the target gene as a result of mutations within the target 
sequence. However, it is also possible that Prevotella isolates possess a different β-
lactamase-encoding gene, e.g. those that encode SHV or CTX-M ESBLs. Furthermore, other 
enzymes that have been correlated with reduced susceptibility to β-lactam antibiotics in 
Prevotella spp. are CfxA-type β-lactamases, in functional subgroup 2e [27]. Previous work 
indicated that this β-lactamase has penicillinase and cephalosporinase properties with low 
MICs of third- and fourth-generation cephalosporins apparent, including cefotaxime and 
ceftazidime [27]. Giraud-Morin et al. also demonstrated that all Prevotella isolates positive 
for a cfxA-type gene (n = 62) were susceptible to ceftazidime [28]. In contrast, in our earlier 
study we identified an association between the presence of the cfxA-type gene and both 
amoxicillin and ceftazidime resistance amongst Prevotella isolates from various sources 
[19]. The reduced ceftazidime susceptibility observed may be due to mutations within the 
amino acid sequence of the CfxA-type β-lactamase, which are spectrum extending, or be the 
consequence of a different resistance mechanism [19,28]. If the former mechanism exists, 
then it is unclear whether production of such a CfxA-type β-lactamase by some Prevotella 
spp. would result in an ESBL phenotype that is detected by the combined disk method.
Moreover, Prevotella isolates may possess more than one gene encoding a β-lactamase. 
Therefore, a systematic evaluation of β-lactamases in Prevotella spp. should now be 
undertaken, e.g. using analytical isoelectric focusing.
The Prevotella isolates from paediatric CF patients were more likely to harbour blaTEM 
compared with isolates from adult CF patients. This may be due to the fact that blaTEM is 
usually plasmid-mediated and it is possible that in older CF patients, where the antibiotic 
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treatment burden is greater compared with younger patients, resistance mechanisms are 
more likely to be chromosomally encoded. To investigate this theory, a longitudinal study is 
needed to assess changes in the location and expression of ESBL-encoding genes in isolates 
during disease progression.
Given that Prevotella spp. are detected as part of a polymicrobial infection in the respiratory 
tract, there is the potential that β-lactamase-producing Prevotella facilitate the persistence of 
susceptible isolates, from the same or different genus, in lethal concentrations of β-lactam 
antibiotics [15]. A recent study found that β-lactamase-producing Bacteroides spp. were able 
to shield a β-lactamase-negative E. coli isolate from the activity of ceftriaxone [29]. 
Likewise, we have shown that a β-lactamase-positive Prevotella isolate protected a 
susceptible P. aeruginosa isolate from the action of ceftazidime. Enabling this recognised 
pathogen to persist in the presence of ceftazidime may therefore be an indirect method by 
which Prevotella contribute to chronic lung infection, and studies focusing on passive 
antibiotic resistance are necessitated to confirm this finding with a larger panel of isolates 
and genera. A limitation of the in vitro co-culture model is that the CF pulmonary 
microbiota is complex with a diverse array of bacteria present and the existence of numerous 
intricate microbial interactions, which may also impact the survival of pathogens in the 
presence of antibiotics. Moreover, it is unlikely that ceftazidime would be administered 
alone in the treatment of CF respiratory exacerbations and this is not reflected by our current 
in vitro model. Nevertheless, when deciding on appropriate antibiotic treatment for 
pulmonary infection, clinicians may need to consider production of β-lactamases by all 
bacteria belonging to the microbiota, which subsequently protect themselves and other 
members of the community from antimicrobial agents.
5. Conclusions
In summary, we have shown that Prevotella isolated from CF airways infection produce 
ESBLs, which potentially contribute to reduced susceptibility to β-lactam antibiotics. 
Genotypic analysis revealed that >40% of Prevotella isolates harboured blaTEM, a clinically 
important β-lactamase-encoding gene in other bacterial genera. These data suggest that 
future studies investigating Prevotella susceptibility should examine the production of 
ESBLs by this genus. This study also supports the hypothesis that β-lactamase-producing 
Prevotella spp. shield recognised CF pathogens from treatment with ceftazidime, potentially 
contributing to the persistence of lung infection.
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• We describe ESBL production by Prevotella from the cystic fibrosis respiratory 
microbiota.
• ESBL production was common among Prevotella isolates.
• Higher MICs of β-lactam antibiotics were detected in ESBL-producing isolates.
• The blaTEM gene was detected in >40% of Prevotella isolates.
• A β-lactamase-positive Prevotella isolate shielded Pseudomonas aeruginosa 
from ceftazidime.
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Comparison of susceptibility (MICs) between ESBL-positive (n = 38) and ESBL-negative (n 
= 12) cystic fibrosis Prevotella isolates. In the box and whisker plot, the top and bottom 
boundaries of each box indicate the 75th and 25th quartile values, respectively, with the line 
inside the box representing the median (50th quartile). End of whiskers indicate the range. 
Any isolates recorded as having an MIC greater than the maximum (>256 mg/L) 
concentration on the Etest strip are shown as double the maximum concentration. MIC, 
minimum inhibitory concentration; ESBL, extended-spectrum β-lactamase.
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Prevalence of ESBL-producing Prevotella isolates from CF patients prescribed long-term 
antibiotics (flucloxacillin, azithromycin, tobramycin and colistin) compared with CF patients 
not prescribed chronic antibiotic treatments. ESBL, extended-spectrum β-lactamase; CF, 
cystic fibrosis.
Sherrard et al. Page 14










Comparison of ESBL production and detection of blaTEM between CF adult (n = 25) and CF 
paediatric (n = 25) isolates. *P < 0.05. ESBL, extended-spectrum β-lactamase; CF, cystic 
fibrosis.
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Time–kill studies (mean ± standard deviation, n = 3) using ceftazidime at 64× the 
Pseudomonas aeruginosa minimum inhibitory concentration (MIC) (32 mg/L). A protective 
effect (antagonism) by Prevotella was defined as a ≥2 log10 increase in viable count of P. 
aeruginosa at 48 h compared with that of the P. aeruginosa isolate alone. *P < 0.05.
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